KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Other Operating Expenses: 2017-2023

Historic Other Operating Expenses for BeOne Medicines (ONC) over the last 5 years, with Jun 2023 value amounting to $188,000.

  • BeOne Medicines' Other Operating Expenses fell 99.74% to $188,000 in Q2 2023 from the same period last year, while for Jun 2023 it was -$136.4 million, marking a year-over-year decrease of 302.20%. This contributed to the annual value of $71.5 million for FY2020, which is 1.40% down from last year.
  • According to the latest figures from Q2 2023, BeOne Medicines' Other Operating Expenses is $188,000, which was up 0.53% from $187,000 recorded in Q1 2023.
  • In the past 5 years, BeOne Medicines' Other Operating Expenses ranged from a high of $76.7 million in Q3 2022 and a low of -$213.5 million during Q4 2022.
  • Moreover, its 3-year median value for Other Operating Expenses was $34.7 million (2021), whereas its average is $37,500.
  • As far as peak fluctuations go, BeOne Medicines' Other Operating Expenses spiked by 229.08% in 2019, and later tumbled by 649.82% in 2021.
  • Quarterly analysis of 5 years shows BeOne Medicines' Other Operating Expenses stood at $18.3 million in 2019, then rose by 16.11% to $21.3 million in 2020, then crashed by 649.82% to -$116.9 million in 2021, then crashed by 82.61% to -$213.5 million in 2022, then tumbled by 99.74% to $188,000 in 2023.
  • Its Other Operating Expenses was $188,000 in Q2 2023, compared to $187,000 in Q1 2023 and -$213.5 million in Q4 2022.